Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for multiple sclerosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Multiplesclerosis: Dantrolene Dantrolene | Prescribing information | Multiplesclerosis | CKS | NICE Search CKS… Menu Dantrolene Multiplesclerosis: Dantrolene Last revised in October 2019 Dantrolene What doses of dantrolene are indicated for spasticity? The dose of dantrolene often needs adjustment for each person, but a typical regimen is: Initial dose: 25 mg daily. Titration: gradually increase the dose at intervals of at least one week. Typically, it is not usual to have to exceed 75 mg
Multiplesclerosis: Scenario: Managing the major symptoms and complications of multiplesclerosis Scenario: Managing complications | Management | Multiplesclerosis | CKS | NICE Search CKS… Menu Scenario: Managing complications Multiplesclerosis: Scenario: Managing the major symptoms and complications of multiplesclerosis Last revised in October 2019 Scenario: Managing the major symptoms and complications of multiplesclerosis From age 18 years onwards. Which complications should be managed (...) in primary care? Many of the complications of multiplesclerosis will be managed by a specialist multidisciplinary team. Consider liaising with members of the multidisciplinary team when taking decisions on management. However, depending on local arrangements and local guidelines, primary care practitioners may have a role to play in the management of a number of symptoms and complications including: How should I manage fatigue in a person with multiplesclerosis? Assess the person for anxiety
Multiplesclerosis: Baclofen Baclofen | Prescribing information | Multiplesclerosis | CKS | NICE Search CKS… Menu Baclofen Multiplesclerosis: Baclofen Last revised in October 2019 Baclofen What doses of baclofen are indicated for spasticity? The dose of baclofen often needs adjustment to suit each person, but a typical regimen is: Initial dose: 5 mg three times a day. Titration: gradually increase the dose every three days. Typical maintenance dose is 60 mg daily in divided doses. Maximum
Multiplesclerosis: Amantadine Amantadine | Prescribing information | Multiplesclerosis | CKS | NICE Search CKS… Menu Amantadine Multiplesclerosis: Amantadine Last revised in October 2019 Amantadine What doses of amantadine are indicated for fatigue? The use of amantadine for fatigue in people with multiplesclerosis (MS) is off-label. The dose most commonly used in the studies evaluating amantadine for MS-related fatigue is 100 mg twice daily. [ ; ] What are the contraindications
Multiplesclerosis: When should I suspect that a person has multiplesclerosis? Initial presentation | Diagnosis | Multiplesclerosis | CKS | NICE Search CKS… Menu Initial presentation Multiplesclerosis: When should I suspect that a person has multiplesclerosis? Last revised in October 2019 When should I suspect that a person has multiplesclerosis? Multiplesclerosis (MS) can affect nearly any part of the central nervous system. Therefore, the presenting symptoms and signs can vary greatly (...) movement abnormalities that can cause diplopia, oscillopsia (a sensation of movement of the vision), nystagmus, and internuclear ophthalmoplegia (inability to adduct one eye and nystagmus in the abducting eye on oculomotor examination). Bulbar muscle problems resulting in dysarthria or dysphagia. Basis for recommendation The information on the possible presentations of multiplesclerosis is based on the National Institute for Health and Care Excellence (NICE) guideline Multiplesclerosis: management
Multiplesclerosis: What else might it be? Differential diagnosis | Diagnosis | Multiplesclerosis | CKS | NICE Search CKS… Menu Differential diagnosis Multiplesclerosis: What else might it be? Last revised in October 2019 What else might it be? No symptom or sign that may occur with multiplesclerosis (MS) is unique to MS, and other conditions often need to be ruled out, especially in the early stages of the disease. These include: Other demyelinating diseases: Neuromyelitis optica — a rare (...) brain lesions — can cause progressive neurological symptoms and signs. Paraneoplastic syndromes — may cause cerebellar ataxia and other neurological symptoms and signs. Basis for recommendation The information on differential diagnoses to consider in a person presenting with possible multiplesclerosis is based on the National Institute for Health and Care Excellence (NICE) guideline Multiplesclerosis: management of multiplesclerosis in primary and secondary care [ ], and in the review articles
Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in MultipleSclerosis NHS England » Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in MultipleSclerosis (all ages) Search Search Menu Urgent Clinical Commissioning Policy Statement: Natalizumab-induced (...) Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in MultipleSclerosis (all ages) Document first published: 14 March 2018 Page updated: 14 March 2018 Topic: , Publication type: This clinical commissioning policy statement is an interim commissioning position pending the formation of a Clinical Policy. Document PDF 74 KB 5 pages
Fampridine (Fampyra) in cases of multiplesclerosis (MS) Fampridine (Fampyra®) in cases of multiplesclerosis (MS) | Report | National Health Care Institute You are here: Fampridine (Fampyra®) in cases of multiplesclerosis (MS) Search within English part of National Health Care Institute Search Fampridine (Fampyra®) in cases of multiplesclerosis (MS) Zorginstituut Nederland carried out an assessment of the medicinal product fampridine (Fampyra®). Based on the outcomes of the assessment
MultiplesclerosisMultiplesclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Multiplesclerosis Last reviewed: February 2019 Last updated: February 2019 Summary Demyelinating central nervous system condition clinically defined by two episodes of neurological dysfunction (brain, spinal cord, or optic nerves) that are separated in space and time. Classically presents in white women, aged between 20 to 40 years (...) , but lends greater specificity when present with brain lesions. Treatment of the condition can be divided into three parts: treatment of the acute attack; prevention of future attacks by reducing triggers and use of disease-modifying therapies; and symptomatic treatments of neurological difficulties such as spasticity, pain, fatigue, and bladder dysfunction. Definition Multiplesclerosis (MS) is defined as an inflammatory demyelinating disease characterised by the presence of episodic neurological
PRAC recommends further restrictions for multiplesclerosis medicine Zinbryta due to risk of serious liver damage PRAC recommends further restrictions for multiplesclerosis medicine Zinbryta due to risk of serious liver damage | European Medicines Agency Search Search Menu PRAC recommends further restrictions for multiplesclerosis medicine Zinbryta due to risk of serious liver damage Press release 27/10/2017 Zinbryta to be used only in a restricted patient group, with strict liver monitoring (...) EMA's ( ) is recommending further restrictions on the use of the multiplesclerosis medicine Zinbryta (daclizumab) following a review of the medicine's effects on the liver. The review found that unpredictable and potentially fatal immune-mediated liver injury can occur during treatment with Zinbryta and for up to 6 months after stopping treatment. In , 1.7% of patients receiving Zinbryta had a serious liver reaction. In order to reduce the risks, doctors should now only prescribe Zinbryta
Antineutrophil Cytoplasmic Antibody andÂ MultipleSclerosis 29854982 2019 02 26 2468-0249 3 3 2018 May Kidney international reports Kidney Int Rep Antineutrophil Cytoplasmic Antibody and MultipleSclerosis. 732-737 10.1016/j.ekir.2017.11.013 George Jason C JC Department of Nephrology, Geisinger Medical Center, Danville, Pennsylvania, USA. Mohan Prince P Department of Nephrology, Geisinger Medical Center, Danville, Pennsylvania, USA. Ho Kevin K Department of Nephrology, Geisinger Medical Center
Comorbidity in multiplesclerosis is associated with diagnostic delays and increased mortality To investigate the effect of chronic comorbidity on the time of diagnosis of multiplesclerosis (MS) and on mortality in MS.We conducted a population-based, nationwide cohort study including all incident MS cases in Denmark with first MS symptom between 1980 and 2005. To investigate the time of diagnosis, we compared individuals with and without chronic comorbidity using multinomial logistic
Clemastine fumarate as a remyelinating therapy for multiplesclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Multiplesclerosis is a degenerative inflammatory disease of the CNS characterised by immune-mediated destruction of myelin and progressive neuroaxonal loss. Myelin in the CNS is a specialised extension of the oligodendrocyte plasma membrane and clemastine fumarate can stimulate differentiation of oligodendrocyte precursor cells in vitro, in animal models (...) , and in human cells. We aimed to analyse the efficacy and safety of clemastine fumarate as a treatment for patients with multiple sclerosis.We did this single-centre, 150-day, double-blind, randomised, placebo-controlled, crossover trial (ReBUILD) in patients with relapsing multiplesclerosis with chronic demyelinating optic neuropathy on stable immunomodulatory therapy. Patients who fulfilled international panel criteria for diagnosis with disease duration of less than 15 years were eligible. Patients were
2017LancetControlled trial quality: predicted high